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Abstract
Resveratrol is a natural phytoestrogen with antiproliferative properties present in red wine, grapes, and berries. Published reports
on the effects of resveratrol in human endometrial function are limited. The objective of this study was to investigate the
expression of estrogen receptor a (ESR1), Ki-67 (a proliferative marker), aryl hydrocarbon receptor (AhR), and members of the
cytochrome P450 superfamily of enzymes (CYP1A1 and CYP1B1) in an in vitro and vivo assay. Alkaline phosphatase assay of
estrogenicity was used to compare estrogen activity of different concentrations of resveratrol to estradiol (E2) and diethylstilbes-
trol (DES), using Ishikawa cell culture. Immunohistochemical expression of ESR1 and Ki67, and reverse transcriptase polymer-
ase chain reaction of AhR, CYP1A1, and CYP1B1 were analyzed from xenograft implants of human endometrial tissue in
ovariectomized immunodeficient RAG-2-g(c) mice, after 30 days of treatment with subcutaneous pellets of E2, E2 plus pro-
gesterone (P4), or E2 plus resveratrol (6, 30, or 60 mg) for 30 days. Compared to E2, resveratrol acted as an agonist and
antagonist of estrogen in low and high concentrations, respectively, when combined with E2. Xenografts of human endome-
trial tissues in RAG-2 mice exhibited reduced expression of ESR1 and proliferative activity (Ki67) with 60 mg of resveratrol.
This study suggests that resveratrol, at high doses, has the potential benefit to reduce proliferation of human endometrium
through ESR1.
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Introduction
Resveratrol (trans-3,5,40-trihydoxystilbene) is a natural phytoes-
trogen synthesized by plants following ultraviolet radiation. Red
wine, grapes, and berries have significant concentrations of this
compound. Resveratrol has been reported to have antineoplas-
tic,1 anti-inflammatory, and antioxidant properties.2 In addition,
resveratrol has been shown to inhibit growth of cancer cell
lines.3-5 Researchers have investigated the antiproliferative
action in endometriosis using in vivo animal and human mod-
els.6-8 Reduction in the size and activity of endometriotic
implants has been observed with the use of resveratrol although
uterine wet weight and endometrial proliferation and protein
kinase B phosphorylation are increased by resveratrol treatment
in the rat.9 Resveratrol also enhances E-cadherin and glycodelin
at sites of intercellular contact in endometrial cell lines, suggest-
ing a possible action for resveratrol in promoting endometrial
receptivity toward implantation.10
Dioxins are potentially toxic polycyclic aromatic hydrocar-
bons that are accumulating in our drinking water and food as a
result of their production as chemical industry by-products. The
long environmental and biological half-life of dioxins coupled
with their hydrophobic nature lead to accumulation in human
and animal adipose tissue. Dioxins bind to and activate the aryl
hydrocarbon receptor (AhR) triggering a variety of biologic
responses. Dioxin has been shown to have effects on estrogen
action and is implicated in the pathogenesis of endometriosis
and other diseases affecting women.11,12
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Endometriosis is a disease that affects 176 million women
worldwide13 and is present in about 60% of adolescent women
with chronic pelvic pain or dysmenorrhea.14 Endometriosis is
defined as the presence of endometrial glands and stroma out-
side the uterine cavity. This condition is characterized by
increased endometrial proliferation and responsiveness to
estrogen and by endometrial resistance to progesterone.15,16
Both eutopic and ectopic endometrium in women with endo-
metriosis overexpress estrogen receptor a (ERa; ESR1)17 per-
haps due to defective progesterone action or excessive estrogen
production.18-20 Estrogen receptor b (ERb; ESR2) is overex-
pressed in endometriosis as well.21,22
Resveratrol has been shown to be an AhR antagonist with
possible protective activity against the effects of dioxins23 and
to have different estrogen action (agonist or antagonist) in dif-
ferent tissues.24 Although resveratrol appears to have potential
bioactivity in human endometrium, data on its effects in human
endometrial function have been limited. To gain insight into
the physiological aspects of resveratrol in human endometrium,
this study will provide the basis for understanding pathophysio-
logical conditions, such as endometriosis.
In this study, we investigated the effect of resveratrol on key
components related to endometrial proliferation, that is, ESR1,
Ki67, AhR, and its downstream target genes CYP1A1 and
CYP1B1, using previously validated methods.25,26 These data
on the effects of resveratrol on endometrial responses to estro-
gen will provide further insight into potential mechanisms of
action of resveratrol that could help explain observed beneficial
effects of this phytoestrogen.
Methods
Alkaline Phosphatase Assay
The relative estrogenicity of resveratrol was studied in vitro,
using the alkaline phosphatase assay in a well-differentiated
endometrial cell line (Ishikawa).26 This cell line maintains ERa
and ERb (ESR1 and ESR2), androgen receptor, and progester-
one receptor and is sensitive to estrogen treatment.27 Unless oth-
erwise stated, all reagents were obtained from Sigma (St Louis,
Missouri). Increased concentrations of resveratrol alone or in
combination with estradiol (E2) treatment were used to study the
relative estrogen activity of both substances. Ishikawa cells were
cultured in medium containing phenol red-free Dulbecco Modi-
fied Eagle Medium:Nutrient Mixture F-12 (DMEM/F-12) for 48
hours before seeding in 96-well plates (BD Bioscience, San Jose,
California). The cells were washed twice with 1 phosphate-
buffered saline (PBS), detached with trypsin–EDTA 0.25% then
resuspended in culture medium. Approximately 2  104 cells
were added to each well with 200 mL medium and grown for
24 hours in a humid chamber at 37C with 5% CO2. The cells
were then switched to phenol red-free DMEM/F-12 medium
containing E2 (108 mol/L) and incubated up to 3 days.
Alkaline phosphatase assay was measured at 24, 48, and
72 hours. Estradiol or diethylstilbestrol (DES) at 108 mol/L,
with or without resveratrol (104-1012 mol/L), or the
antiestrogen Imperial Chemical Industries (ICI 182780—
106 mol/L, Zeneca Pharmaceuticals, Wilmington, Delaware)
were incubated for 72 hours. The medium was changed daily
and all experiments were performed in quadruplicates. After
72 hours of incubation, the alkaline phosphatase assay was per-
formed. Cells were washed twice with PBS. Next, plates were
frozen at80C for 10 minutes and then thawed to lyze the cell
membranes. Cold soluble substrate of 20 mL consisting of Sig-
maFast p-nitrophenyl phosphate tablets dissolved in deionized
H2O was added to each well on ice. The substrate solution pro-
duced a yellow color when alkaline phosphatase was present.
After 1 to 3 hours of incubation at room temperature, the absor-
bance was read in a plate-reader at 405 nm (Biorad, Hercules,
California). Each experiment was repeated 3 times with a min-
imum of 3 wells per each replicate assay.
Animal Protocols and Hormone Treatments
This study was approved by the Greenville Health System (GHS)
Institutional Animal use and Care Committee protocol. The
RAG-2g(c) knockout mice (C57BL/6J  C57BL/10SgSnAi[-
KO]gc[KO]Rag-2—n ¼ 20) were purchased from Taconic
(Taconic Germantown, Philadelphia) and then housed under bar-
rier and standard husbandry conditions. Female RAG mice were
ovariectomized using sterile technique and allowed to recover for
a least 1 week prior further surgery. The 20 animals were divided
into 5 treatment groups (n¼ 4 in each group): (1) E2 alone, (2) E2
plus progesterone (P), (3) E2 plus 6 mg of resveratrol, (4) E2 plus
30 mg of resveratrol, and (5) E2 plus 60 mg of resveratrol. Resver-
atrol and the hormones were administered via implanted subcuta-
neous time-release hormone pellets (E2: 100mg/pellet; P: 7.5 mg/
pellet—Innovative Research of America, Sarasota, Florida) that
were placed along the dorsal paravertebral regions bilaterally as
described.28 The hormone pellets were designed to deliver a
steady concentration daily dose of E2 and progesterone of 1.6
mg/d for up to 60 days and 357 mg/d for 21 days, respectively.
Likewise, resveratrol pellets were designed to release a steady
concentration of 6, 30, or 60 mg/d.
Human Xenografts
Human endometrial biopsies were obtained from cycling
women at the time of laparoscopy using a pipelle device and
the tissue was placed into Hams F12 medium for transport to
the laboratory. Collection of human tissues was performed
according to institutional review board-approved protocols at
GHS, and all patients signed a written consent to allow the use
of their tissue for research. In the laboratory, uniform samples
(2 mm3) were dissected and placed into 2 separate positions in
subcutaneous pockets on the abdomen of the ovariectomized,
anesthetized RAG-2 mice. The incisions containing the xeno-
graft implants were closed with 5-0 Vicryl (Ethicon, Piscat-
away, New Jersey) interrupted suture. At the end of 4 weeks,
the mice were killed and the xenograft implants which were
visible under the skin and easily identified were collected and
analyzed (Figure 1).
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Immunohistochemistry
Each endometrial sample collected from the xenograft tissue
was analyzed by immunocytochemistry for ERa (NCL-L-ER-
6F11—dilution 1:250, Leica Biosystems, Newcastle, United
Kingdom) and Ki67 (MKI67—dilution 1:75—Biogenex, San
Ramon, California), a nuclear marker of cell proliferation,
according to previous publication.29 For this purpose, the col-
lected xenograft tissue was fixed in 10% buffered formalin
solution and then paraffin embedded. Sections of 5-mm thick
were obtained and immunostained for ESR1 and Ki67. Semi-
quantitative HSCORE was assigned in a blinded manner by 2
investigators (BAL and SCA) and the results were compared
between groups. The use of HSCORE has been previously
validated as a semiquantitative assay for immunohistochem-
ical staining.30
Reverse Transcriptase Polymerase Chain Reaction
Tissue samples were homogenized in 600 mL of buffer RLT
(Qiagen RNeasy Mini) using a Tissue Tearor (BioSpec Prod-
ucts, Bartlesville, Oklahoma) at 4C. The Qiagen RNeasy Mini
Kit (Valencia, California) was then used for the isolation of
RNA from the lysate according to the manufacturer’s instruc-
tions. RNA was quantified using the Quant-iT RiboGreen RNA
Assay Kit (Invitrogen Molecular Probes, Eugene, Oregon) and
a CytoFluor Multi-Well Plate Reader Series 4000 (Perseptive
Biosystems, Framingham, Massachusetts) according to the
manufacturers’ instructions.
The production and amplification of complementary DNA
were measured in a single reaction in a DNA Opticon 2 System
(MJ Research, Inc, Waltham, Massachusetts) using 2 SYBR
Green Master Mix and Multiscribe Reverse Transcriptase
(Applied Biosystems, Inc, Foster City, California). The primer
sequences were: AhR, 50-GTGCACAGCTCTGCTTCAGT-30
and 50-CTACTCCACTTCAGCCACCA-30; CYP1A1, 50-CGG
CCCCGGCTCTCT-30 and 50-GTGTCGGAAGGTCTCCCAG
GAT-30; and CYP1B1, 50-ATACAAGGCAGACGGTCCCT-30
and 50-CTGCTCCTCCTCTTCACCAG-30 The reverse tran-
scriptase polymerase chain reaction (RT-PCR) used the following
cycles: 48 C for 30 minutes, 95C for 10 minutes, and 40 cycles
of 58C for 1 minute and 95C for 10 seconds. The RT-PCR
data were performed using the 2(Sample Ct  GAPDH Ct] method,
as described previously.31
The cytosolic AhR was analyzed because of its crosstalk
with estrogen receptor and regulation of the expression of sev-
eral isoforms of cytochrome P450, including CYP1A1 and
CYP1B1. CYP1A1, and CYP1B1 are responsible for E2 hydro-
xylation.32 The AhR has been linked as an antiestrogenic and is
a ligand to resveratrol.33
Figure 1. Composite showing the RAG2-g(c) knockout mouse model for endometriosis. Subcutaneous implants of human endometrium
were stimulated by treatment with estrogen pellets for 4 weeks. The implants are visible under the skin (A), visible endometrial xenografts
(B) are harvested (C) and the histologic appearance is shown in D (scale bar ¼ 100 mm). In a typical experiment, 2 implants would be placed
and the mice treated with E2 plus 1 of 3 doses of resveratrol prior to tissue collection after 30 days.
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Statistical Analysis
Comparison of results was made on Prism Software 6.0
(GraphPad, Inc, San Diego, CA) using analysis of variance
with Dunn corrections for multiple comparisons. Statistical sig-
nificance was assigned for P < .05.
Results
In Vitro Assay
Three days of incubation of Ishikawa cells with E2 at 108 mol/L
resulted in the highest estrogen activity according to the alka-
line phosphatase assay (Figure 2A). Based on these results,
subsequent assays were done with 3 days of treatment. The
comparison of different doses of resveratrol with E2 revealed
that resveratrol at 104 mol/L had little estrogenic activity but
combined with E2 it acted as an estrogen antagonist. In con-
trast, low doses of resveratrol (1011 and 1012 mol/L) with
E2 displayed an agonistic effect (Figure 2B).
In Vivo Assay
A mouse model using human endometrial xenograft implants
demonstrated that resveratrol exerted biologic activity on
human endometrial tissues in vivo. Overall weight of the
recovered tissues after a month of treatment was not signifi-
cantly different among treatment groups (data not shown).
Immunostaining for Ki67 and ESR1 revealed a different
immunostaining expression among different forms of treatment
(Figures 3 and 4). Mice treated with E2 plus P or E2 plus
resveratrol showed decreased cell proliferation (Figure 3C) as
well as reduced ESR1 (Figure 3A). The reduction in ESR1 was
not as profound with resveratrol as with E2 plus P (Figure 4),
but at the highest dose (60 mg) resveratrol exhibited a reduction
in both ESR1 and Ki-67 in endometrial epithelial cells (Figure
3A and C). In stromal cells, ESR1 levels were reduced by E2
plus P, but not by resveratrol (Figure 3B), and Ki-67 expression
was reduced specifically by resveratrol in human endometrial
stroma in the presence of 60 mg/d of resveratrol (Figure 3D).
To further investigate the possibility that resveratrol was
acting through AhR, we examined AhR itself, and 2 down-
stream target proteins of AhR, CYP1A1, and CYP1B1. The
RT-PCR was performed on messenger RNA (mRNA) isolated
from the implants recovered from the RAG mice treated with
E2, E2 plus P, and E2 plus 60 mg of resveratrol. The reduction
of AhR with resveratrol was not significant among any of the
treatment groups (Figure 5). Likewise, mRNA expression of
CYP1A1 and CYP1B1 was not significantly different com-
pared to E2 or E2 plus progesterone (Figure 5).
Discussion
There is increasing interest in the dietary components of food
and the possible benefits of specific compounds on health and
disease. In the present study, we used both in vivo and in vitro
techniques to investigate the role of an active component of red
wine in endometrial activity. Resveratrol alone appears to have
weak estrogen activity in Ishikawa cells. In the presence of
estrogen, however, it acts as both an estrogen agonist and an
estrogen antagonist at low and high concentrations, respec-
tively (Figure 2B). These findings are in accordance with those
published by Bowes et al whose work provided more serial
dilutions with resveratrol in a cell line transfected with ERa
and ERb.34 The mechanism for the antagonistic effect at higher
concentrations does not appear to be related to estrogen meta-
bolism, since the effect is seen with the nonmetabolizable syn-
thetic estrogen, DES, (Figure 1B). Increased cellular toxicity of
high-dose resveratrol was not ruled out in this study but has not
been shown by others.35,36
We demonstrate that resveratrol slows endometrial prolif-
eration of xenografts using the immunocompromised mouse
model. Others have observed this reduction in proliferation.36
Although the mechanism for this effect on blocking prolifera-
tion has been proposed to be antagonism of estrogen through
AhR,37 we find no difference in AhR activity in resveratrol-
treated and untreated xenograft samples. We also did not find
evidence for direct effects of resveratrol on ESR1 levels that
paralleled proliferation data (Ki67 immunostaining). Immunohis-
tochemical analysis of eutopic human implants in RAG-2g(c)
knockout mice (Figure 3) suggests that the antiestrogenic, anti-
proliferative activity of resveratrol may be related to reduction















































































































































Figure 2. A, Estrogenicity in Ishikawa cells after treatment of est-
radiol during different time periods. Alkaline phosphatase assay of
Littlefield provided a means to compare the estrogenicity. ANOVA
P < .0001, n¼ 4 in each group. B, Estrogenicity obtained from Ishikawa
cells treated for 3 days with different concentrations of resveratrol in
the presence or absence of estradiol or DES at 108 mol/L, or with
DES þ ICI (an antiestrogen). Bars represent mean (+SEM); post hoc
test (pairing letters), all P < .05. ANOVA indicates analysis of variance;
DES, diethylstilbestrol; ICI, Imperial Chemical Industries; SEM, stan-
dard error of the mean.
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of ESR1 specifically in endometrial epithelium. These results
are in accordance with those published by Kang et al.36
Furthermore, resveratrol has been shown to act through
nongenomic action of alternative estrogen receptors such as
GPR3038 and might be acting through alternative estrogen
receptors such as ESR2.24
Figure 3. Immunohistochemical appearance of estrogen receptor a (ERa) and the proliferation marker Ki67 in human eutopic endometrium
used as a xenografts tissue recovered from the mouse model (mean + SEM). A, ERa expression in epithelial endometrium is reduced in the
presence of treatment with estradiol (1.6 mg/d) and progesterone (357 mg/d) and with estradiol (1.6 mgþ resveratrol 60 mg/d. B, ERa expression
is reduced in stroma cells, compared to those treated with estradiol only. Ki-67 expression is reduced in endometrial stromal cells treated with
estradiol plus progesterone (C and D). All ANOVA—Dunnett post hoc test (pairing letters)—All P  .01. Epi indicates epithelial endometrium;
SEM, standard error of the mean.
Figure 4. Photomicrograph of human eutopic endometrium used a xerograph in RAG mouse. Estrogen treated implants contained more estro-
gen receptors and Ki67, a marker of proliferation, than the implants from mice treated with E2 plus progesterone (E2 þ P). In contrast to the
E2-treated animals, mice treated with 60 mg of resveratrol (E2 þ R) had reduced Ki67 and ERa immunostaining. Magnification 400. E2 indi-
cates estradiol; P, progesterone; R, resveratrol; ERa, estrogen receptor a.
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Animal models have proven useful for the study of endo-
metriosis. Although primate models have become the most
applicable in vivo model to date,21,39 rodent models of endo-
metriosis are more accessible and less expensive.40,41 Using the
nude mouse model, other researchers were able to study xeno-
grafts of human endometrial tissue more effectively.42 The use
of the RAG-2 knockout mice has been previously characterized
and demonstrated to be an eloquent model for studying hormo-
nal responses of human endometriotic tissues.25 Our studies
have used this particular mouse model for the study of the
effect of herbal treatments on endometriosis.29
Resveratrol appears to be a more potent in vivo antiestrogen
at higher doses tested (60 mg). More recently, Chen et al
reported that resveratrol inhibits the expression of CYP1A1
and CYP1B1 induced by dioxin (2,3,7,8-tetrachlrodibenzeno-
p-dioxin—TCDD) binding to AhR.33 Likewise, Casper et al
found that resveratrol competes with AhR in the presence of
an AhR ligand, such as TCCD, and inhibits CYP1A1 activity.23
With our sample size, we were not able to find a difference big-
ger than 50% among the mean expression of CYP1A1,
CYP1B1, or AhR when xenograft implants were treated with
E2 plus 60 mg of resveratrol (Figure 4). Possible explanations
for this discrepancy might be related to the different dosages
used in each study and the use of an active AhR agonist, dioxin
or TCDD, in the studies by Chen et al. Indeed, the use 50 mmol/L
of resveratrol alone did not elicit the expression of CYP1A1 or
CYP1B1 but 50 mmol/L of resveratrol with 2 nmol/L of TCDD
inhibits CYP1A1 and CYP1B1 expression at the mRNA and
protein level.33 Despite differences in the resveratrol doses
used between these studies, the low concentration of resvera-
trol in combination with E2, used in our in vitro study, yielded
a higher estrogenic activity, consistent with the results of Bhat
and Pezzuto.24
The findings of our study, including the reduction in endo-
metrial ESR1, specifically in endometrial epithelium in
response to resveratrol, suggest that this compound may pro-
vide a novel approach to the treatment of endometriosis.
Bulun has suggested that ESR2 acts as an antiestrogen in
endometriosis43 and ESR2–ESR1 ratios are higher in endo-
metriosis.44 Resveratrol acts through both estrogen recep-
tors45 but has different actions in each estrogen receptor
type.46 Future studies will examine the possibility that resver-
atrol is acting to induce ESR2 as a mechanism for these noted
effects. The dose of 60 mg/d of resveratrol used in our animal
model corresponds to an unusual high dose of resveratrol for
humans. However, a recent study7 using a 30-mg pill per day
in 12 patients with endometriosis provided an important clin-
ical ground to pursuit a larger clinical trial. Oral micronized
resveratrol (SRT501) can reach up to 185 mmol/L in human
plasma and it is well tolerated.47 Together with our results,
and the knowledge accumulated on the pharmacokinetics,
bioavailability of oral resveratrol,48 different formula-
tions,47,49 and enhancers for bioavailability,50 the path for
larger and well-designed clinical trials is open.
In summary, using both in vivo and in vitro models we
demonstrated that resveratrol acts as an antiestrogen in vivo
and in vitro at high concentrations in Ishikawa cells and in
human endometrium. The immunocompromised mouse
model demonstrated that cellular proliferation in human
endometrial xenografts declines in parallel with decreasing
epithelial ERa levels. The mechanism of this reduced prolif-
eration remains to be determined. Since overexpression or
overactivity of estrogen receptor has been proposed as a cen-
tral defect leading to infertility in women with endometriosis,
and critical biomarkers of endometrial receptivity have been
shown to be inhibited by overexpression of ESR1,17 it is pos-
sible that resveratrol may have other potential benefits for the
treatment of infertility. Given the compounding effects of
alcohol in reproductive-aged women and the impracticality
and expense involved in achieving therapeutic doses, it seems
unlikely that red wine would be a convenient source for
resveratrol treatment by itself. Purified resveratrol com-

























































Figure 5. Comparisons are shown for AhR, Cyp1A1, and Cyp1B1
mRNA by RT-PCR (mean + SEM) in human xenografts endometrial
tissue from RAG-2 mice treated with estradiol (E2), E2 plus proges-
terone (P), or E2 plus 60 mg of resveratrol. No significant difference
was found among groups. AhR indicates aryl hydrocarbon receptor;
mRNA, messenger RNA; RT-PCR, reverse transcriptase polymerase
chain reaction; SEM, standard error of the mean.
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